Mizuho Securities analyst Vamil Divan maintained a Buy rating on Evolus (EOLS – Research Report) today and set a price target of $8.00. The company’s shares closed last Friday at $4.84, close to its 52-week low of $3.12.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.2% and a 43.7% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and Karuna Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evolus with a $8.00 average price target, representing a 94.2% upside. In a report issued on May 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
Based on Evolus’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $10.5 million and GAAP net loss of $19.74 million. In comparison, last year the company had a GAAP net loss of $10.98 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.